Hietamäki Johanna, Kärkinen Juho, Iivonen Anna-Pauliina, Vaaralahti Kirsi, Tarkkanen Annika, Almusa Henrikki, Huopio Hanna, Hero Matti, Miettinen Päivi J, Raivio Taneli
Helsinki University Hospital, New Children's Hospital, Pediatric Research Center, Helsinki 00014, Finland.
Department of Physiology, Medicum Unit, Faculty of Medicine, and Stem Cells and Metabolism Research Program, Research Programs Unit, University of Helsinki, Helsinki 00014, Finland.
EClinicalMedicine. 2022 Jul 18;51:101556. doi: 10.1016/j.eclinm.2022.101556. eCollection 2022 Sep.
Childhood-onset combined pituitary hormone deficiency (CPHD) has a wide spectrum of etiologies and genetic causes for congenital disease. We aimed to describe the clinical spectrum and genetic etiologies of CPHD in a single tertiary center and estimate the population-level incidence of congenital CPHD.
The retrospective clinical cohort comprised 124 CPHD patients (48 with congenital CPHD) treated at the Helsinki University Hospital (HUH) Children's Hospital between 1985 and 2018. Clinical data were collected from the patient charts. Whole exome sequencing was performed in 21 patients with congenital CPHD of unknown etiology.
The majority (61%;76/124) of the patients had acquired CPHD, most frequently due to craniopharyngiomas and gliomas. The estimated incidence of congenital CPHD was 1/16 000 (95%CI, 1/11 000-1/24 000). The clinical presentation of congenital CPHD in infancy included prolonged/severe neonatal hypoglycaemia, prolonged jaundice, and/or micropenis/bilateral cryptorchidism in 23 (66%) patients; despite these clinical cues, only 76% of them were referred to endocrine investigations during the first year of life. The median delay between the first violation of the growth screening rules and the initiation of GH Rx treatment among all congenital CPHD patients was 2·2 years, interquartile range 1·2-3·7 years. Seven patients harbored pathogenic variants in and , and one patient carried a likely pathogenic variant in (c.676G>A, p.(Ala226Thr)).
Our study suggests that congenital CPHD can occur in 1/16 000 children, and that patients frequently exhibit neonatal cues of hypopituitarism and early height growth deflection. These results need to be corroborated in future studies and might inform clinical practice.
Päivikki and Sakari Sohlberg Foundation, Biomedicum Helsinki Foundation, and Emil Aaltonen Foundation research grants.
儿童期起病的联合垂体激素缺乏症(CPHD)病因广泛,涉及先天性疾病的多种病因及遗传因素。我们旨在描述单一三级医疗中心CPHD的临床特征和遗传病因,并估算先天性CPHD的人群发病率。
回顾性临床队列研究纳入了1985年至2018年间在赫尔辛基大学医院(HUH)儿童医院接受治疗的124例CPHD患者(48例先天性CPHD患者)。从患者病历中收集临床数据。对21例病因不明的先天性CPHD患者进行了全外显子测序。
大多数患者(61%;76/124)为获得性CPHD,最常见病因是颅咽管瘤和胶质瘤。先天性CPHD的估计发病率为1/16000(95%CI,1/11000 - 1/24000)。23例(66%)先天性CPHD婴儿期临床表现包括持续性/重度新生儿低血糖、持续性黄疸和/或小阴茎/双侧隐睾;尽管有这些临床提示,但其中仅76%在出生后第一年内接受了内分泌检查。所有先天性CPHD患者首次违反生长筛查规则至开始生长激素治疗的中位延迟时间为2.2年,四分位间距为1.2 - 3.7年。7例患者在 和 基因中存在致病变异,1例患者在 基因中携带可能的致病变异(c.676G>A,p.(Ala226Thr))。
我们的研究表明,先天性CPHD在每16000名儿童中可能出现1例,且患者常表现出垂体功能减退的新生儿线索和早期身高生长偏差。这些结果需要在未来研究中得到证实,并可能为临床实践提供参考。
派维姬和萨卡里·索尔贝里基金会、赫尔辛基生物医学基金会以及埃米尔·阿尔托宁基金会研究资助。